Israel Biotech Fund is a venture capital firm established in 2014 and located in Rehovot, Israel, which is recognized as a key hub for biotechnology in the country. The firm specializes in investing in clinical stage biotechnology and pharmaceutical companies, particularly those based in Israel or with strong connections to the region. By focusing on therapeutic assets, Israel Biotech Fund aims to maximize the success of its portfolio companies, which are typically at or near clinical development stages. The firm boasts a team of 25 Venture Advisors, composed of distinguished industry leaders who provide strategic guidance and support to help companies achieve sustainable growth. Through its investments, Israel Biotech Fund not only seeks high-value returns for its investors but also contributes to the advancement of Israel's biotechnology sector, thereby enhancing investment opportunities in the burgeoning industry.
Vensica is focused on developing an innovative ultrasound-based drug delivery system aimed at improving the treatment of urinary bladder conditions, particularly bladder cancer and overactive bladder (OAB). Traditional treatment methods involve instilling medication directly into the bladder via a catheter, which can be inefficient and painful. Vensica's approach utilizes ultrasound to enhance drug uptake and penetration into the bladder wall, facilitating a quick and pain-free procedure for patients. This method aims to increase the effectiveness of treatments and reduce the high recurrence rates associated with bladder cancer, which can be as high as 70%. By leveraging ultrasound technology, Vensica seeks to provide safer and more effective treatment options for individuals suffering from these conditions.
Nectin Therapeutics
Series A in 2022
Nectin Therapeutics Ltd., founded in 2017 and based in Jerusalem, Israel, specializes in the development of monoclonal antibodies targeting members of the Nectin family of receptors and ligands. These antibodies are designed to address immune checkpoint mechanisms that play a crucial role in cancer immunotherapy. By focusing on both solid and hematological malignancies, Nectin Therapeutics aims to create therapies that can overcome the inhibitory pathways utilized by tumors, thereby enhancing the ability of immune cells to eradicate cancer cells. The company's innovative approach seeks to improve patient outcomes in cancer treatment.
MediWound
Post in 2022
MediWound Ltd. is a biopharmaceutical company that specializes in the development, manufacturing, and commercialization of innovative therapeutic products aimed at addressing unmet medical needs, particularly in the areas of severe burns and chronic wounds. Founded in 2000 and headquartered in Yavne, Israel, it markets NexoBrid, a biopharmaceutical agent designed for the removal of eschar, or dead tissue, in patients with severe burns. NexoBrid has completed clinical development and is approved for use in Europe. The company is also advancing other products in its pipeline, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic wounds, and MWPC003 for connective tissue disorders. MediWound aims to improve patient outcomes and reduce the complications associated with traditional surgical interventions in wound management.
Vensica
Venture Round in 2021
Vensica is focused on developing an innovative ultrasound-based drug delivery system aimed at improving the treatment of urinary bladder conditions, particularly bladder cancer and overactive bladder (OAB). Traditional treatment methods involve instilling medication directly into the bladder via a catheter, which can be inefficient and painful. Vensica's approach utilizes ultrasound to enhance drug uptake and penetration into the bladder wall, facilitating a quick and pain-free procedure for patients. This method aims to increase the effectiveness of treatments and reduce the high recurrence rates associated with bladder cancer, which can be as high as 70%. By leveraging ultrasound technology, Vensica seeks to provide safer and more effective treatment options for individuals suffering from these conditions.
Splisense
Series B in 2021
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
BioSight
Series C in 2020
BioSight is a biopharmaceutical company focused on developing innovative cancer-targeted chemotherapy pro-drugs. Founded in 2000 and based in Lod, Israel, BioSight has developed a technology known as S2DOT, which allows for the targeted delivery of chemotherapy drugs directly into cancer cells. This approach significantly reduces the systemic toxicity often associated with traditional chemotherapy treatments. The company’s lead product is a non-toxic conjugate of cytarabine and asparagine, designed specifically for the treatment of acute myeloid leukemia. Through its research and development efforts, BioSight aims to provide safe and effective therapeutic options for patients suffering from hematological malignancies and disorders.
BioSight
Series C in 2020
BioSight is a biopharmaceutical company focused on developing innovative cancer-targeted chemotherapy pro-drugs. Founded in 2000 and based in Lod, Israel, BioSight has developed a technology known as S2DOT, which allows for the targeted delivery of chemotherapy drugs directly into cancer cells. This approach significantly reduces the systemic toxicity often associated with traditional chemotherapy treatments. The company’s lead product is a non-toxic conjugate of cytarabine and asparagine, designed specifically for the treatment of acute myeloid leukemia. Through its research and development efforts, BioSight aims to provide safe and effective therapeutic options for patients suffering from hematological malignancies and disorders.
Ayala Pharmaceuticals
Series B in 2019
Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company based in Rehovot, Israel, founded in 2017. The company specializes in developing small molecule therapeutics for rare and aggressive cancers, focusing on genetically defined patient populations. Its lead product candidate is AL101, an intravenous gamma secretase inhibitor currently in Phase II clinical trials for treating recurrent/metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala Pharmaceuticals is developing AL102, an oral gamma secretase inhibitor in Phase I clinical trials for desmoid tumors. The company has a collaboration agreement with Novartis to develop AL102 for multiple myeloma. Ayala's approach involves using bioinformatics and next-generation sequencing to identify and address tumorigenic drivers of cancer, aiming to deliver targeted therapies to underserved patient populations.
Biond Biologics
Series B in 2019
Biond Biologics Ltd is a clinical-stage biopharmaceutical company based in Misgav, Israel, specializing in drug discovery and development for cancer immunotherapy and autoimmune diseases. Founded in 2016, the company focuses on creating innovative therapies that address unmet medical needs. Biond is dedicated to uncovering immunoregulatory pathways and conducting internal research on immune checkpoints and immune-evasion mechanisms. Its novel platform aims to enable antibody-targeting of intracellular immune factors, facilitating the development of immuno-oncology drugs and treatments for autoimmune disorders. Through its commitment to high-quality science and innovative approaches, Biond Biologics seeks to provide breakthrough therapies that can effectively combat critical health conditions.
Ayala Pharmaceuticals
Series A in 2018
Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company based in Rehovot, Israel, founded in 2017. The company specializes in developing small molecule therapeutics for rare and aggressive cancers, focusing on genetically defined patient populations. Its lead product candidate is AL101, an intravenous gamma secretase inhibitor currently in Phase II clinical trials for treating recurrent/metastatic adenoid cystic carcinoma in patients with Notch-activating mutations. Additionally, Ayala Pharmaceuticals is developing AL102, an oral gamma secretase inhibitor in Phase I clinical trials for desmoid tumors. The company has a collaboration agreement with Novartis to develop AL102 for multiple myeloma. Ayala's approach involves using bioinformatics and next-generation sequencing to identify and address tumorigenic drivers of cancer, aiming to deliver targeted therapies to underserved patient populations.
Gamida Cell
Series F in 2017
Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.
Pharma Two B
Series C in 2017
Pharma Two B Ltd. is a specialty pharmaceuticals company based in Rehovot, Israel, with a subsidiary in the United States. Founded in 2007, the company focuses on developing clinically differentiated and value-added products based on approved drugs, particularly through fixed-dose combinations (FDCs) that feature two or more drugs with complementary effects. Its primary therapeutic areas of interest are Parkinson's disease and various types of cancer, including pancreatic, lung, and breast cancer. Pharma Two B aims to address significant unmet medical needs by utilizing a US 505b2 regulatory approach, which facilitates shorter approval timelines. The company also develops generic products with non-infringing formulations and licenses these products for development and commercialization through milestone and royalty arrangements.
Vidac Pharma Holding
Series A in 2016
Vidac Pharma Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel, focused on developing innovative medicines for oncologic and dermatologic diseases. The company is dedicated to creating first-in-class therapies to address significant unmet medical needs, particularly in the treatment of various skin cancers, including non-melanoma and melanoma types, as well as conditions like cutaneous T-cell lymphoma and actinic keratosis. Vidac's lead product, VDA-1102, is an ointment currently undergoing clinical trials for actinic keratosis and cutaneous T-cell lymphoma. Additionally, the company is advancing another molecule, VDA-1275, which has potential applications for a broad range of solid tumors. Vidac Pharma's unique approach involves targeting the VDAC/HK2 system, which is specific to malignant cells, allowing for selective apoptosis of cancer cells while preserving healthy tissue.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.